Trade PROCEPT BioRobotics Corporation - PRCT CFD

Add to favourite

51.00

1.3%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.15

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Key Stats

Prev. Close*	51.67
Open*	51.53
1-Year Change*	39.5%
Day's Range*	51 - 53.74
52 wk Range	24.83-49.39
Average Volume (10 days)	727.12K
Average Volume (3 months)	10.84M
Market Cap	2.28B
P/E Ratio	-100.00K
Shares Outstanding	50.50M
Revenue	116.39M
EPS	-2.33
Dividend (Yield %)	N/A
Beta	-100.00K
Next Earnings Date	Feb 27, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	51.00	-0.86	-1.66%	51.86	53.78	50.92
Apr 17, 2024	51.67	-0.77	-1.47%	52.44	52.89	51.54
Apr 16, 2024	51.94	1.99	3.98%	49.95	52.09	49.70
Apr 15, 2024	50.53	-0.56	-1.10%	51.09	52.57	50.19
Apr 12, 2024	50.66	-1.79	-3.41%	52.45	52.45	50.29
Apr 11, 2024	53.22	0.64	1.22%	52.58	54.39	52.45
Apr 10, 2024	52.15	1.96	3.91%	50.19	52.21	49.51
Apr 9, 2024	51.66	2.63	5.36%	49.03	51.66	48.50
Apr 8, 2024	49.35	2.41	5.13%	46.94	49.46	46.91
Apr 5, 2024	46.98	1.18	2.58%	45.80	48.44	45.09
Apr 4, 2024	45.65	-0.88	-1.89%	46.53	46.92	45.50
Apr 3, 2024	46.50	0.22	0.48%	46.28	47.54	46.04
Apr 2, 2024	46.51	0.47	1.02%	46.04	47.12	45.41
Apr 1, 2024	46.91	-2.46	-4.98%	49.37	49.37	46.70
Mar 28, 2024	49.31	0.26	0.53%	49.05	50.36	49.05
Mar 27, 2024	48.70	2.29	4.93%	46.41	48.76	46.00
Mar 26, 2024	46.29	-1.08	-2.28%	47.37	47.56	45.96
Mar 25, 2024	46.92	-0.72	-1.51%	47.64	48.46	46.75
Mar 22, 2024	47.58	-0.93	-1.92%	48.51	49.15	47.56
Mar 21, 2024	48.75	0.53	1.10%	48.22	50.01	48.22

PROCEPT BioRobotics Corporation Events

Time (UTC)	Country	Event
Wednesday, May 1, 2024
Time (UTC) 12:00	Country US	Event Q1 2024 Procept Biorobotics Corp Earnings Call Q1 2024 Procept Biorobotics Corp Earnings Call Forecast - Previous -
Time (UTC) 20:00	Country US	Event Q1 2024 PROCEPT BioRobotics Corp Earnings Release Q1 2024 PROCEPT BioRobotics Corp Earnings Release Forecast - Previous -
Friday, May 3, 2024
Time (UTC) 13:00	Country US	Event Procept Biorobotics Corp To Host AUA Investor Day Procept Biorobotics Corp To Host AUA Investor Day Forecast - Previous -
Wednesday, May 15, 2024
Time (UTC) 16:20	Country US	Event Procept Biorobotics Corp at Bank of America Health Care Conference Procept Biorobotics Corp at Bank of America Health Care Conference Forecast - Previous -
Friday, June 14, 2024
Time (UTC) 15:00	Country US	Event Procept Biorobotics Corp Annual Shareholders Meeting Procept Biorobotics Corp Annual Shareholders Meeting Forecast - Previous -
Thursday, July 25, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 PROCEPT BioRobotics Corp Earnings Release Q2 2024 PROCEPT BioRobotics Corp Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019
Total revenue	75.014	34.473	7.717	6.169
Revenue	75.014	34.473	7.717	6.169
Cost of Revenue, Total	37.929	18.608	8.972	8.054
Gross Profit	37.085	15.865	-1.255	-1.885
Total Operating Expense	158.996	88.637	55.519	49.719
Selling/General/Admin. Expenses, Total	88.828	51.036	30.272	28.518
Research & Development	28.981	18.993	16.275	13.147
Operating Income	-83.982	-54.164	-47.802	-43.55
Interest Income (Expense), Net Non-Operating	-3.172	-5.753	-5.402	0.379
Other, Net	0	0.064	0.185	1.196
Net Income Before Taxes	-87.154	-59.853	-53.019	-41.975
Net Income After Taxes	-87.154	-59.853	-53.019	-41.975
Net Income Before Extra. Items	-87.154	-59.853	-53.019	-41.975
Net Income	-87.154	-59.853	-53.019	-41.975
Income Available to Common Excl. Extra. Items	-87.154	-59.853	-53.019	-41.975
Income Available to Common Incl. Extra. Items	-87.154	-59.853	-53.019	-41.975
Diluted Net Income	-87.154	-59.853	-53.019	-41.975
Diluted Weighted Average Shares	44.4	43.676	42.2695	42.2695
Diluted EPS Excluding Extraordinary Items	-1.96293	-1.37039	-1.25431	-0.99303
Diluted Normalized EPS	-1.88955	-1.37039	-1.25431	-0.99303
Unusual Expense (Income)	3.258

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	33.104	24.404	23.777	20.349	16.691
Revenue	33.104	24.404	23.777	20.349	16.691
Cost of Revenue, Total	14.675	11.913	13.101	10.118	8.205
Gross Profit	18.429	12.491	10.676	10.231	8.486
Total Operating Expense	58.729	52.781	52.075	42.454	34.566
Selling/General/Admin. Expenses, Total	32.441	30.131	26.034	24.754	19.655
Research & Development	11.613	10.737	9.682	7.582	6.706
Operating Income	-25.625	-28.377	-28.298	-22.105	-17.875
Interest Income (Expense), Net Non-Operating	0.34	-0.107	0.126	-0.508	-1.309
Other, Net			0
Net Income Before Taxes	-25.285	-28.484	-28.172	-22.613	-19.184
Net Income After Taxes	-25.285	-28.484	-28.172	-22.613	-19.184
Net Income Before Extra. Items	-25.285	-28.484	-28.172	-22.613	-19.184
Net Income	-25.285	-28.484	-28.172	-22.613	-19.184
Income Available to Common Excl. Extra. Items	-25.285	-28.484	-28.172	-22.613	-19.184
Income Available to Common Incl. Extra. Items	-25.285	-28.484	-28.172	-22.613	-19.184
Diluted Net Income	-25.285	-28.484	-28.172	-22.613	-19.184
Diluted Weighted Average Shares	45.16	45.066	44.772	44.64	44.324
Diluted EPS Excluding Extraordinary Items	-0.5599	-0.63205	-0.62923	-0.50656	-0.43281
Diluted Normalized EPS	-0.5599	-0.63205	-0.55646	-0.50656	-0.43281
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Unusual Expense (Income)			3.258

Annual
Quarterly

	2022	2021	2020	2019
Total Current Assets	272.626	326.173	110.256	50.736
Cash and Short Term Investments	221.859	304.32	100.13	42.021
Cash & Equivalents	212.989	290.699	100.13	42.021
Total Receivables, Net	15.272	4.464	1.549	1.099
Accounts Receivable - Trade, Net	15.272	4.464	1.549	1.099
Total Inventory	28.543	13.977	7.477	6.686
Prepaid Expenses	6.175	2.586	0.369	0.312
Other Current Assets, Total	0.777	0.826	0.731	0.618
Total Assets	309.329	337.024	125.971	61.995
Property/Plant/Equipment, Total - Net	32.137	8.324	12.915	8.273
Property/Plant/Equipment, Total - Gross	41.141	15.018	17.703	10.515
Accumulated Depreciation, Total	-9.004	-6.694	-4.788	-2.242
Intangibles, Net	1.477	1.75	2.023	2.295
Other Long Term Assets, Total	3.089	0.777	0.777	0.691
Total Current Liabilities	35.29	16.242	14.526	6.79
Accounts Payable	9.391	2.029	1.24	1.444
Accrued Expenses	20.682	11.205	7.824	3.132
Notes Payable/Short Term Debt	0	0	0	0
Current Port. of LT Debt/Capital Leases		0	4.551	0
Other Current Liabilities, Total	5.217	3.008	0.911	2.214
Total Liabilities	112.257	69.933	65.011	32.764
Total Long Term Debt	51.213	50.004	44.407	23.224
Long Term Debt	51.213	50.004	44.407	23.224
Other Liabilities, Total	25.754	3.687	6.078	2.75
Total Equity	197.072	267.091	60.96	29.231
Redeemable Preferred Stock	0	0	243.854	173.068
Common Stock	0.00045	0.00044	0.00042	0.00042
Additional Paid-In Capital	545.753	528.666	18.788	4.808
Retained Earnings (Accumulated Deficit)	-348.675	-261.521	-201.668	-148.649
Unrealized Gain (Loss)	-0.006	-0.054	-0.014	0.004
Other Equity, Total	-0.00045	-0.00044	-0.00042	-0.00042
Total Liabilities & Shareholders’ Equity	309.329	337.024	125.971	61.995
Total Common Shares Outstanding	44.828	43.676	42.2695	42.2695
Cash	8.87	13.621

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	368.668	230.016	245.58	272.626	288.932
Cash and Short Term Investments	287.087	149.691	180.972	221.859	249.217
Cash & Equivalents	277.784	145.756	178.333	212.989	237.14
Total Receivables, Net	34.622	33.173	20.642	15.272	12.838
Accounts Receivable - Trade, Net	34.622	33.173	20.642	15.272	12.838
Total Inventory	42.201	42.636	38.926	28.543	22.358
Prepaid Expenses	3.981	3.739	4.263	6.175	4.519
Other Current Assets, Total	0.777	0.777	0.777	0.777
Total Assets	421.125	272.446	284.458	309.329	324.037
Property/Plant/Equipment, Total - Net	47.731	37.92	34.38	32.137	29.544
Property/Plant/Equipment, Total - Gross	58.938	48.139	44.095	41.141
Accumulated Depreciation, Total	-11.207	-10.219	-9.715	-9.004
Intangibles, Net	1.273	1.341	1.409	1.477	1.545
Other Long Term Assets, Total	3.453	3.169	3.089	3.089	4.016
Total Current Liabilities	41.356	35.945	32.504	35.29	27.359
Accounts Payable	13.597	10.036	10.341	9.391	6.331
Accrued Expenses	14.967	12.303	10.406	20.682	12.757
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total	12.792	13.606	11.757	5.217	8.271
Total Liabilities	121.769	116.544	111.332	112.257	103.275
Total Long Term Debt	51.307	51.275	51.241	51.213	50.692
Long Term Debt	51.307	51.275	51.241	51.213	50.692
Other Liabilities, Total	29.106	29.324	27.587	25.754	25.224
Total Equity	299.356	155.902	173.126	197.072	220.762
Redeemable Preferred Stock	0	0	0	0	0
Common Stock	0.0005	0.00045	0.00045	0.00045	0.00045
Additional Paid-In Capital	726.428	558.352	550.27	545.753	541.048
Retained Earnings (Accumulated Deficit)	-427.066	-402.444	-377.159	-348.675	-320.503
Unrealized Gain (Loss)	-0.006	-0.006	0.015	-0.006	0.217
Other Equity, Total	-0.0005	-0.00045	-0.00045	-0.00045	-0.00045
Total Liabilities & Shareholders’ Equity	421.125	272.446	284.458	309.329	324.037
Total Common Shares Outstanding	50.473	45.271	45.009	44.828	44.714
Cash	9.303	3.935	2.639	8.87	12.077

Annual
Quarterly

	2022	2021	2020	2019
Net income/Starting Line	-87.154	-59.853	-53.019	-41.975
Cash From Operating Activities	-80.382	-57.334	-48.343	-43.818
Cash From Operating Activities	2.841	3.324	2.86	1.494
Non-Cash Items	15.418	3.902	2.299	0.195
Cash Interest Paid	4.291	4.75	3.969	0.397
Changes in Working Capital	-11.487	-4.707	-0.483	-3.532
Cash From Investing Activities	-2.653	-0.592	-0.233	43.153
Capital Expenditures	-2.653	-0.592	-0.233	-7.611
Other Investing Cash Flow Items, Total			0	50.764
Cash From Financing Activities	3.612	262.116	106.771	26.527
Issuance (Retirement) of Stock, Net	6.417	262.116	82.086	1.994
Issuance (Retirement) of Debt, Net	1.195	0	24.685	24.533
Net Change in Cash	-79.423	204.19	58.195	25.862
Financing Cash Flow Items	-4

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-28.484	-87.154	-58.982	-36.369	-17.185
Cash From Operating Activities	-35.928	-80.382	-55.208	-35.357	-18.231
Cash From Operating Activities	0.793	2.841	2.178	1.475	0.758
Non-Cash Items	4.473	15.418	8.297	4.109	1.492
Cash Interest Paid	1.121	4.291	3.573	2.369	1.171
Changes in Working Capital	-12.71	-11.487	-6.701	-4.572	-3.296
Cash From Investing Activities	-5.339	-2.653	-1.787	-0.273	-0.055
Capital Expenditures	-5.339	-2.653	-1.787	-0.273	-0.055
Other Investing Cash Flow Items, Total
Cash From Financing Activities	0.38	3.612	4.93	4.153	1.291
Issuance (Retirement) of Stock, Net	0.38	6.417	4.93	4.153	1.291
Issuance (Retirement) of Debt, Net		1.195			0
Net Change in Cash	-40.887	-79.423	-52.065	-31.477	-16.995
Financing Cash Flow Items		-4

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

PROCEPT BioRobotics Corporation Company profile

About Procept Biorobotics Corp

Procept Biorobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). Its AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. It designs Aquablation therapy to deliver outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Procept Biorobotics Corp revenues increased from $7.7M to $34.5M. Net loss increased 13% to $59.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest expense increase of 10% to $5.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.25 to -$1.38.

Industry:

Medical Equipment, Supplies & Distribution (NEC)

900 Island Drive
Suite 210
REDWOOD CITY
CALIFORNIA 94065
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024